Mario Mondelli

Dr. Mario Mondelli

Unit of Clinical Immunology - Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of Hepatology
Verified
Journal Article
Closed access
GRGiovanni Raimondo
Giovanni Raimondo
JAJean-Pierre Allain
Jean-Pierre Allain
Maurizia Rossana BrunettoMaurizia Rossana Brunetto
Maurizia Rossana Brunetto
MBMarie-Annick Buendia
Marie-Annick Buendia
DCDing-Shinn Chen
Ding-Shinn Chen
Fabien ZoulimFabien Zoulim
Fabien Zoulim

1 September 2009 in Gastroenterology
Verified
Journal Article
Closed access
BOBarbara Oliviero
Barbara Oliviero
SVStefania Varchetta
Stefania Varchetta
EPEnrica Paudice
Enrica Paudice
GMGiuseppe Michelone
Giuseppe Michelone
MZMarco Zaramella
Marco Zaramella
Mario MondelliMario Mondelli
Mario Mondelli

1 December 1982 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Mario MondelliMario Mondelli
Mario Mondelli
GVG M Vergani
G M Vergani
AAA Alberti
A Alberti
DVD Vergani
D Vergani
BPB Portmann
B Portmann
RWR Williams
R Williams
Peripheral blood T lymphocytes from 21 patients with chronic HBV infection were incubated with autologous hepatocytes in a microcytotoxicity assay. Cytotoxicity was significantly increased in 13 cases, and in 12 of these the cytotoxic effect of the T lymphocytes was inhibited by preincubating the liver cells with IgG containing antibodies to the hepatitis B core antigen (HBcAg). Normal human IgG and IgG containing antibodies to the hepatitis B surface antigen (HBsAG) were without effect. Control experiments using autologous fibroblasts as target cells showed low levels of T cell cytotoxicity and no blocking effect of anti-core antibody. All patients in whom it was possible to demonstrate HBcAg in liver tissue had significantly increased T cell cytotoxicity to autologous hepatocytes. These studies suggest that T cell cytotoxicity in patients with chronic HBV infection is directed against determinants resembling the hepatitis B core antigen on the plasma membrane of hepatocytes.

2 March 2009 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DFDebora Franceschini
Debora Franceschini
MPMarino Paroli
Marino Paroli
VFVittorio Francavilla
Vittorio Francavilla
MVMelissa Videtta
Melissa Videtta
SMStefania Morrone
Stefania Morrone
Vincenzo BarnabaVincenzo Barnaba
Vincenzo Barnaba
CD4+CD25+Foxp3+ Tregs suppress autoimmune responses. In addition, they limit T cell responses during chronic infection, thereby minimizing T cell–dependent immunopathology. We sought to investigate how Tregs are regulated in the livers of patients chronically infected with HCV, where they control the balance between an adequate protective immune response and suppression of immunopathology. We found that, despite accumulating and proliferating at sites of infection in the livers of patients chronically infected with HCV, Tregs were relatively less expanded than CD4+CD25+Foxp3– effector T cells. The relative lower expansion of intrahepatic Tregs coincided with their upregulation of programmed death–1 (PD-1). PD-1 expression inversely correlated with both Treg proliferation and clinical markers of immune suppression in vivo. Consistent with the possibility that PD-1 controls Tregs, blockade of the interaction between PD-1 and programmed death–1 ligand 1 (PD-L1) enhanced the in vitro expansion and function of Tregs isolated from the livers of patients chronically infected with HCV. Blockade of the interaction between PD-L1 and B7.1 also improved the proliferation of these cells. Interestingly, both PD-1 and phosphorylated STAT-5 were overexpressed in intrahepatic Tregs in a parallel fashion in steady disease conditions, and in an alternate-fluctuating fashion during the course of severe hepatitis reactivation. Notably, PD-L1 blockade upregulated STAT-5 phosphorylation in Tregs ex vivo. These data suggest that PD-L1 negatively regulates Tregs at sites of chronic inflammation by controlling STAT-5 phosphorylation.

1 March 1997 in Hepatology
Verified
Journal Article
Open access
PDF file
SBS Bruno
S Bruno
ESE Silini
E Silini
ACA Crosignani
A Crosignani
FBF Borzio
F Borzio
GLG Leandro
G Leandro
Mario MondelliMario Mondelli
Mario Mondelli
A prospective study was performed to establish whether infection with specific hepatitis C virus (HCV) genotypes was associated with an increased risk of development of hepatocellular carcinoma (HCC) in cirrhosis. A cohort of 163 consecutive hepatitis C virus antibody (anti– HCV)–positive cirrhotic patients was prospectively evaluated for the development of HCC at 6–month intervals by ultrasound (US) scan and α–fetoprotein (AFP) concentration. HCV genotypes were determined according to Okamoto. Risk factors associated with cancer development were analyzed by univariate and multivariate statistics. At enrollment, 101 patients (62%) were infected with type 1b, 48 (29.5%) were infected with type 2a/c, 2 (1.2%) were infected with type 3a, 1 (0.6%) was infected with type 1a, 3 (1.8%) had a mixed–type infection, and, in 8 patients (4.9%), genotype could not be assigned. After a 5– to 7–year follow–up (median, 68 months), HCC developed in 22 of the patients, 19 infected with type 1b and 3 with type 2a/c (P < .005). Moreover, HCC developed more frequently in males (P < .01), patients with excessive alcohol intake (P < .01), those over 60 years of age (P < .02), and in patients who did not receive interferon treatment (P < .02). Multivariate analysis showed that type 1b was the most important risk factor associated with tumor development (odds ratio 6.14, 1.77–21.37 95% confidence interval). Other independent risk factors were older age and male sex. Cirrhotic patients infected with HCV type 1b carry a significantly higher risk of developing HCC than patients infected by other HCV types. The latter may require a less intensive clinical surveillance for the early detection of neoplasia.

15 October 2020 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
SVStefania Varchetta
Stefania Varchetta
DMDalila Mele
Dalila Mele
BOBarbara Oliviero
Barbara Oliviero
SMStefania Mantovani
Stefania Mantovani
SLSerena Ludovisi
Serena Ludovisi
Mario MondelliMario Mondelli
Mario Mondelli
The relationship between severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and host immunity is poorly understood. We performed an extensive analysis of immune responses in 32 patients with severe COVID-19, some of whom succumbed. A control population of healthy subjects was included. Patients with COVID-19 had an altered distribution of peripheral blood lymphocytes, with an increased proportion of mature natural killer (NK) cells and low T-cell numbers. NK cells and CD8+T cells overexpressed T-cell immunoglobulin and mucin domain-3 (TIM-3) and CD69. NK cell exhaustion was attested by increased frequencies of programmed cell death protein 1 (PD-1) positive cells and reduced frequencies of natural killer group 2 member D (NKG2D)-, DNAX accessory molecule-1 (DNAM-1)- and sialic acid-binding Ig-like lectin 7 (Siglec-7)-expressing NK cells, associated with a reduced ability to secrete interferon (IFN)γ. Patients with poor outcome showed a contraction of immature CD56brightand an expansion of mature CD57+FcεRIγnegadaptive NK cells compared to survivors. Increased serum levels of IL-6 were also more frequently identified in deceased patients compared to survivors. Of note, monocytes secreted abundant quantities of IL-6, IL-8, and IL-1β which persisted at lower levels several weeks after recovery with concomitant normalization of CD69, PD-1 and TIM-3 expression and restoration of CD8+T cell numbers. A hyperactivated/exhausted immune response dominate in severe SARS-CoV-2 infection, probably driven by an uncontrolled secretion of inflammatory cytokines by monocytes. These findings unveil a unique immunological profile in COVID-19 patients that will help to design effective stage-specific treatments for this potentially deadly disease.